Plain-English translation of NCT06974929 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Breast Cancer research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing HRS-6209, a new medication, to see if it works better when combined with standard breast cancer treatments like letrozole. Researchers want to understand whether this combination is safe, how your body processes it, and whether it can slow or stop cancer growth in women whose cancer has continued to grow despite previous treatment.
Current breast cancer treatments don't work for everyone, and some patients' cancer continues to progress. This study is exploring whether adding this medication to existing therapies might help more patients control their disease.
You likely qualify if…
You likely don't qualify if…
You would take the new medication along with one of the standard breast cancer drugs (either letrozole alone, or letrozole combined with another medication) at regular clinic visits. The study team will monitor your safety with blood tests and imaging scans, measure how the medication works in your body, and check whether your cancer is responding to treatment. The study involves about 80 participants total, and your individual commitment would include regular appointments to receive treatment and undergo safety monitoring.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
China